Page last updated: 2024-08-21

indazoles and su 11248

indazoles has been researched along with su 11248 in 282 studies

Research

Studies (282)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (6.03)	29.6817
2010's	231 (81.91)	24.3611
2020's	34 (12.06)	2.80

Authors

Authors	Studies
Rini, BI	3
Kanetake, H; Koga, S	1
Chew, K; Fong, K; Jaeger, E; Rini, BI; Sein, N; Simko, J; Small, EJ; Waldman, FM; Weinberg, V	1
Eto, M; Naito, S	1
Mancuso, A; Sternberg, CN	1
George, DJ	1
Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L	1
Armand, JP; Mir, O; Ropert, S	1
Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M	1
Bukowski, RM; Vakkalanka, BK	1
Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B	1
Cella, D	1
Crouthamel, MC; Gontarek, RR; King, AG; Kumar, R; Levin, RA; Rominger, DH; Tummino, PJ	1
Sherman, SI	1
Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A	1
Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C	1
Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P	1
Choueiri, TK	1
Deville, JL; Duffaud, F; Huynh, T; Salas, S	1
Chen, E; Coatney, RW; Davis, CB; Frazier, KS; French, KJ; Gales, TL; Hu, CX; McSurdy-Freed, J; Renninger, JP; Storck, LM; Zhao, S	1
Figlin, RA; Pal, SK	1
Biró, K; Küronya, Z	1
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R	1
Maráz, A	1
Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH	1
Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R	1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
Chan, AL; Leung, HW	1
Bergmann, L; Gschwend, J; Keilholz, U; Miller, K	1
Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C	1
Canter, D; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Uzzo, RG	1
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K	1
Joly, F	1
Grünberger, B	1
Canter, DJ; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Sirohi, M; Street, R; Uzzo, RG	1
Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V	1
Appleman, LJ; Carlson, DM; Chen, J; Cho, D; Choueiri, TK; Coates, A; Ernstoff, MS; Gupta, N; Kollmannsberger, CK; Michaelson, MD; Perry, DJ; Posadas, EM; Pradhan, R; Qian, J; Ricker, JL; Scappaticci, FA; Tannir, NM; Wong, YN	1
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S	1
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C	1
Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B	1
Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA	1
Buonerba, C; De Placido, S; Di Lorenzo, G	1
Döme, B; Török, S	1
Haddad, H; Rini, BI	1
Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K	1
Boleti, E; Chowdury, S; Crabb, SJ; Jones, R; Nathan, P; Powles, T; Protheroe, A; Rashid, S; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P	1
Halfdanarson, TR; Naraev, BG; Strosberg, JR	1
Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR	1
Borker, R; Fonseca, E; Hess, G	1
Pal, SK; Vogelzang, NJ	1
Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z	1
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P	1
Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E	1
Robert, C; Sibaud, V	1
Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD	1
Caulfield, TR; Cooper, SJ; Copland, JA; Marlow, LA; Tan, WW; Tun, HW; von Roemeling, CA; Wei, JJ; Wu, K	1
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T	1
Arrowsmith, ER; Crane, EJ; Franco, LA; Hainsworth, JD; Khatcheressian, J; Rubin, MS	1
Bono, P; Joensuu, H; Peltola, K; Rautiola, J; Utriainen, T	1
Amantini, C; Berardi, R; Bonfili, L; Burattini, L; Cascinu, S; Eleuteri, AM; Farfariello, V; Liberati, S; Morelli, MB; Mozzicafreddo, M; Nabissi, M; Santoni, G; Santoni, M	1
Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N	1
Soulières, D	1
Barney, BM; Bauer, HJ; Laack, NN; Macdonald, OK; Markovic, SN; Miller, RC; Olivier, KR; Sarkaria, JN	1
Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS	1
Boleti, E; Cella, D; Choueiri, TK; Crescenzo, R; De Giorgi, U; de Souza, P; Deen, K; Fife, K; Guo, J; Hackshaw, MD; Harmenberg, U; Hawkins, R; Hutson, TE; Jin, J; Jones, R; McCann, L; Merchan, JR; Motzer, RJ; Nathan, P; Pandite, LN; Reeves, J; Staehler, M; Sternberg, CN; Uemura, H; Wang, J	1
Heng, DY; Molina, AM; Motzer, RJ	1
Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C	1
Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P	1
Carpenter, C; Choueiri, TK; Deen, KC; Johnson, T; Motzer, RJ; Pandite, LN; Xu, CF; Xue, Z	1
Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M	1
Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A	1
Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T	1
Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ	1
Choi, CL; Cui, W; Han, YF; Hu, SQ; Lee, MY; Mak, SH; Rong, JH; Tsim, WK; Wang, YQ; Xu, DP; Zhang, ZJ	1
Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L	1
Behera, R; Mensa-Wilmot, K; Thomas, SM	1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R	1
Ferrari, S; Paioli, A; Palmerini, E	1
Bono, P; Cella, D; De Giorgi, U; Diaz, J; Eisen, T; Escudier, B; Gschwend, JE; Hawkins, R; Khan, S; Mehmud, F; Négrier, S; Parikh, O; Porta, C; Powles, T; Redhu, S; Sevin, E; Sternberg, CN	1
Garnick, MB	1
Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D	1
Liang, H	1
Choueiri, TK; Deen, K; Hutson, TE; McCann, L; Motzer, RJ	1
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ	1
Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN	1
Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P	1
Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P	1
Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M	1
Elkord, E; Gilham, DE; Hawkins, RE; Shablak, A	1
Blomqvist, LK; Farnebo, J; Grybäck, P; Harmenberg, U; Laurell, A; Sandström, P; Ullén, A; Wersäll, P	1
Abdel-Rahman, O; Fouad, M	1
Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E	1
Acharyya, S; Chopra, A; Fay, AP; Haaland, B; Lopes, Gde L	1
Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N	1
Nishiyama, T; Niwa, N; Ozu, C; Saito, S; Yagi, Y	1
Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M	1
Raj, N; Reidy-Lagunes, D	1
Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L	1
Adelaiye, R; Barrera, G; Ciamporcero, E; Ku, S; Miles, KM; Pili, R; Pizzimenti, S; Ramakrishnan, S; Sennino, B; Shen, L	1
Casciano, R; Chua, A; Culver, K; Garrison, LP; Gorritz, M; Liu, Z; Pal, S; Perrin, A; Sherman, S; Wang, X	1
Albiges, L; Escudier, B; Fizazi, K; Iacovelli, R; Loriot, Y; Massard, C; Massari, F	1
Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P	1
Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB	1
Benson, P; Carpenter, C; Choueiri, TK; de Souza, P; Deen, K; Fay, AP; Figueroa, DJ; Gagnon, R; Ho, TH; Liu, Y; Motzer, RJ; Pandite, L; Powles, T; Signoretti, S	1
Arondekar, B; Deen, KC; Hackshaw, MD; Hansen, RN; Nagar, SP; Ramsey, SD; Sullivan, SD	1
Amdahl, J; Delea, TE; Diaz, J; Hackshaw, MD; Nakhaipour, HR	1
Ito, T; Kutikov, A	1
Bergh, J; Borregaard, J; Dalhus, M; Damkier, P; Ersbøll, J; Hofland, K; Mickisch, G; Pieters, R; Pignatti, F; Salmonson, T; Skibeli, V; Slot, KB; Sylvester, R; Thoresen, H; Tzogani, K; Westgaard, I	1
He, CS; Huang, JK; Lin, QZ; Xie, M	1
Azijli, K; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Honeywell, RJ; Peters, GJ; Poel, D; Rovithi, M; Verheul, HM	1
Bing, N; Choueiri, TK; Davis, ID; Deen, KC; Esteban, E; Garcia-Donas, J; Johnson, T; McCann, L; Motzer, RJ; Pandite, LN; Rodríguez-Antona, C; Spraggs, CF; Sternberg, CN; Whittaker, JC; Xu, CF; Xue, Z	1
Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ	1
Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF	1
Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C	1
Burton, TM; Byfield, SA; Hackshaw, MD; McPheeters, JT; Nagar, SP	1
Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P	1
Atkinson, BJ; Corn, PG; Jonasch, E; Kalra, S; Karam, JA; Matin, SF; Matrana, MR; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wood, CG	1
Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T	1
Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM	1
Bex, A; Blank, CU; Broeks, A; de Gruijl, TD; Gadiot, J; Guislain, A; Haanen, JB; Jordanova, ES; Kaiser, A; Sanders, J; van Boven, H	1
Schmidinger, M; Wittes, J	1
Huang, J; Shan, L; Song, Y; Zhang, HT	1
Kato, S	1
Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A	1
Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS	1
Covell, LL; Ganti, AK	1
Tomita, Y	1
Racsa, PN; Whisman, TR; Worley, K	1
Fujisawa, M; Harada, K; Imai, S; Miyake, H	1
Beaumont, JL; Cella, D; Diaz, J; Khan, S; Lai, JS	1
Bahl, A; Brown, J; Buchan, S; Hawkins, R; Jones, R; Pickering, L; Porfiri, E; Wagstaff, J	1
Crawford, K; Dusing, M; Frischer, JS; Knod, JL	1
Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W	1
Grünwald, V; Ivanyi, P	1
Fujisawa, M; Miyake, H; Miyazaki, A	1
Cartenì, G; Vitale, MG	1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ	1
Kichenadasse, G; Mangoni, AA; Rowland, A; Sorich, MJ; Woodman, RJ	2
Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D	1
Carpenter, C; Figlin, RA; Goldstein, D; McCann, L; Pandite, L; Rosenberg, JE; Townsend, RR	1
Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ	1
Czarnecka, AM; Kornakiewicz, A; Solarek, W; Szczylik, C	1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C	1
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M	1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C	1
Granovetter, M	1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S	1
Delea, TE; Diaz, J; Latimer, N; Mehmud, F; Motzer, RJ; Pandite, L; Sternberg, CN	1
Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C	1
Beaumont, JL; Cella, D; Deen, KC; Diaz, J; Hackshaw, MD; McCann, L; Motzer, RJ; Powles, T; Salsman, JM	1
Kononenko, OA; Stakhovskiy, EO; Stakhovskiy, OE; Vitruk, YV; Voylenko, OA; Vukalovych, PS	1
Chittoria, N; Dreicer, R; Elson, P; Garcia, JA; Haddad, H; Jonasch, E; Rini, BI; Tannir, NM; Wood, LS	1
Bergmann, L; Maute, L	1
Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M	1
Keck, B; Lieb, V; Lüdecke, G; Sikic, D	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1
Andrikou, K; Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Montironi, R; Scartozzi, M; Zizzi, A	1
Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Quivy, A; Ravaud, A	1
Eaddy, M; Hackshaw, MD; Holmes, M; Lankford, M; Ogbonnaya, A; Thomas, M	1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R	1
Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X	1
Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S	1
De Groot, S; Haanen, JB; Kiemeney, LA; Oosterwijk, E; Redekop, WK; Sleijfer, S; Uyl-de Groot, CA	1
Abe, H; Arai, K; Fukuda, T; Kamai, T; Masuda, A; Nukui, A; Yoshida, K	1
Annala, M; Azad, AA; Chi, KN; Fazli, L; Mo, F; Nappi, L; Wyatt, AW	1
Kim, JH; Lee, JL; Park, I	1
Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M	1
Cisar, LA; Harnett, J; Hoang, CJ; MacLean, E; Mardekian, J	1
Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J	1
Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK	1
Beuselinck, B; Bjarnason, GA; Choueiri, TK; Donskov, F; Fraccon, AP; Heng, DY; Lee, JL; Pasini, F; Pezaro, C; Ptak-Chmielewska, A; Rini, BI; Ruiz-Morales, JM; Sim, HW; Sliwczynsk, A; Swierkowski, M; Szczylik, C; Teter, Z; Wells, JC; Wood, LA; Yuasa, T	1
Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A	1
Golčić, M; Petković, M	1
Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T	1
Campanario, R; Juárez, A; Saiz, R; Soto, M	1
Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L	1
Chi, Y; Cui, CX; Du, CX; Song, Y; Sun, Y; Sun, YK; Wang, JW; Yang, L; Zhang, W; Zhou, AP	1
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M	1
Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolè, F; Verri, E	1
Broncel, M; Crosier, S; Daley, F; Finetti, MA; Holmes, K; Huang, PH; Jenks, A; Luczynski, MT; McCarthy, F; Natrajan, RC; Payne, LS; Ryall, KA; Tan, AC; Tanos, B; Todd, JR; Vyse, S; Wai, P; Williamson, D; Wong, JP	1
Bedke, J; Stühler, V	1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A	1
Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C	1
Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A	1
Bono, P; Peltola, K; Penttilä, P; Poussa, T; Rautiola, J	1
Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML	1
Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R	1
Capri, S; Delea, TE; Porta, C	1
Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H	1
Laguna, MP	1
Ghate, SR; Li, N; Liu, Z; Pal, SK; Perez, JR; Signorovitch, JE; Vogelzang, NJ; Zichlin, ML	1
Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C	1
Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M	1
Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L	1
Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML	1
Morimoto-Kamata, R; Yui, S	1
Ardizzoni, A; Berardi, R; Bersanelli, M; Biasco, E; Buti, S; Cossu Rocca, M; De Giorgi, U; Fornarini, G; Galli, L; Guida, A; Iacovelli, R; Lolli, C; Masini, C; Massari, F; Mosca, A; Nolè, F; Pastorino, A; Pinto, C; Sabbatini, R; Santoni, M; Terrone, C; Tortora, G	1
Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S	1
Amdahl, J; Chandiwana, D; Delea, TE; Diaz, J; Park, J; Sharma, A	1
Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R	1
Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M	1
Dalhaug, A; Nieder, C; Norum, J; Pawinski, A; Syed, MA	1
Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL	1
Ariad, S; Douvdevani, A; Dresler, H; Keizman, D; Mermershtain, W; Neulander, EZ; Riff, R; Rouvinov, K; Shani-Shrem, N	1
Agarwal, N; Ghate, SR; Li, N; Meiselbach, MK; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML	2
'Aho, T; Armitage, JN; Eisen, T; Fife, K; Klatte, T; Matakidou, A; Riddick, AC; Sachdeva, M; Stewart, GD; Welsh, SJ	1
Buchler, T; Chloupkova, R; Dusek, L; Fiala, O; Finek, J; Kiss, I; Kopeckova, K; Kopecký, J; Lakomy, R; Melichar, B; Petrakova, K; Poprach, A; Slaby, O; Studentova, H; Zemanova, M	1
Ativitavas, T; Kongsuphon, N; Konmun, J; Ngamphaiboon, N; Soukavanitch, M; Teeraaumpornpunt, N	1
Bakouny, Z; Eid, R; Haddad, FG; Kattan, J; Kourie, HR	1
Dietrich, M; Grünwald, V; Pond, GR	1
Albersen, M; Bastin, J; Bechter, O; Beuselinck, B; Clement, P; Decallonne, B; Dumez, H; Lerut, E; Oyen, R; Punie, K; Schöffski, P; Vanderschueren, D; Verbiest, A; Werbrouck, E; Wildiers, H; Woei-A-Jin, FJ; Wolter, P	1
Ahmad, Q; Azad, A; Carrasco-Alfonso, MJ; Chang, YH; Chung, J; Davis, ID; Guo, J; Han, J; Jin, J; Lee, JL; Lim, HY; Motzer, R; Nanua, B; Oya, M; Rha, SY; Takahashi, S; Tatsugami, K; Uemura, H; Wu, HC	1
Basso, U; Bearz, A; Berruti, A; Bracarda, S; Buti, S; Cartenì, G; Caserta, C; Cognetti, F; Cortesi, E; De Giorgi, U; Fornarini, G; Galli, L; Giannarelli, D; Lo Re, G; Pignata, S; Porta, C; Procopio, G; Rastelli, F; Sabbatini, R; Sternberg, CN; Turci, D	1
Amann, K; Büttner, A; Büttner-Herold, M; Daniel, C; Klewer, M; Pfister, F	1
Arellano, C; Bernardes-Génisson, V; Bijani, C; Paludetto, MN; Puisset, F; Robert, A	1
Arroyo, A; Choueiri, TK; Dean, M; Escudier, B; Geertsen, PF; George, D; Grande, E; Gross-Goupil, M; Gurney, H; Kollmannsberger, C; Markby, DW; Motzer, RJ; Pal, S; Park, SH; Pikiel, J; Powles, T; Rha, SY; Suarez, C	1
Bastos, DA; Bonadio, RRCC; Dzik, C; Isaacsson Velho, P; Marta, GN; Muniz, DQB; Nardo, M; Souza, MCLA	1
Basappa, N; Bjarnason, GAG; Dragomir, A; Heng, D; Jewett, M; Kapoor, A; Kollmannsberger, C; Lévesque, E; Nazha, S; Reaume, MN; Soulières, D; Tanguay, S; Wood, L	1
Albiges, L; Barthélémy, P; Bouleftour, W; Chevreau, C; Culine, S; Espenel, S; Fizazi, K; Gravis, G; Guillot, A; Houede, N; Joly, C; Mahammedi, H; Meriaux, E; Negrier, S; Oriol, M; Pouessel, D; Roubaud, G; Tartas, S; Tinquaut, F; Vassal, C	1
Amin, A; Bauer, TM; Berghorn, E; Carducci, M; Ernstoff, MS; Hammers, HJ; Heng, DYC; Knox, J; Kollmannsberger, C; Lewis, LD; McDermott, DF; Plimack, ER; Rini, BI; Spratlin, J; Voss, MH; Yang, L	1
Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gavalas, N; Gkerzelis, I; Karavasilis, V; Kostouros, E; Koutras, A; Koutsoukos, K; Samantas, E; Tzannis, K; Zagouri, F	1
Ravaud, A	1
Bae, WK; Byun, SS; Chung, HS; Chung, J; Hong, SH; Hwang, EC; Hwang, JE; Jeong, CW; Jung, SI; Kim, MS; Kwak, C; Kwon, DD; Park, JY; Seo, SI; Song, C	1
Borchiellini, D	1
Jeon, SY; Lee, NR; Yim, CY	1
Albiges, L; Auclin, E; Auvray, M; Barthelemy, P; Bono, P; De Velasco, G; Escudier, B; Gravis, G; Gross-Goupil, M; Kellokumpu-Lehtinen, P; Mouillet, G; Mourey, L; Powles, T; Priou, F; Rolland, F; Vano, YA	1
Çiçin, İ; Demircan, NC; Erdoğan, B; Gökyer, A; Hacıoğlu, MB; Köstek, O; Tunçbilek, N; Uzunoğlu, S; Yılmaz, E	1
Anota, A; Berthod, D; Bonnetain, F; Es-Saad, I; Fritzsch, J; Meurisse, A; Mouillet, G; Mouyabi, K; Paget-Bailly, S; Pozet, A; Thiery-Vuillemin, A; Vernerey, D	1
Chen, S; Gong, P; Huang, C; Lowerison, MR; Lucien, F; Song, P; Wang, D	1
Fukuda, H; Iizuka, J; Ishida, H; Ishihara, H; Kobayashi, H; Kondo, T; Okumi, M; Takagi, T; Tanabe, K; Yoshida, K	1
Skubitz, KM	1
Abbas, H; Alam, T; Faust, G; Nair, A; Paskins, J; Uccello, M	1
Donskov, F; Fristrup, N	1
Cao, Z; Deng, H; Hong, Z; Huang, Y; Wei, Y; Yuan, X; Zhang, W	1
Bauernhofer, T; Gerritsmann, H; Kratochvill, F; Kretz, M; Loidl, W; Marszalek, M; Mitterberger, M; Mraz, B; Niedersüß-Beke, D; Pfleger, G; Pichler, R; Schmidinger, M; Stöger, H; Tinchon, C; Tulchiner, G; Vogl, U; Wiesinger, CG	1
Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E	1
Bagrodia, A; Bowman, I; Brugarolas, J; Choy, H; Christie, A; Courtney, K; Desai, N; Garant, A; Hammers, H; Hannan, R; Margulis, V; Mohamad, O; Schoenhals, J; Singla, N; Timmerman, R; Wang, C; Zhang, Y	1
Costa, RSD; Couto, DHN; Meirelles, IO	1
Arellano, C; Bernardes-Génisson, V; Chatelut, E; Paludetto, MN; Puisset, F; Robert, A; Stigliani, JL	1
Aspinall, SL; Becker, D; Cunningham, FE; Geraci, MC; Good, CB; Heron, BB; Lee, S; Prasad, V; Zhao, X	1
Bjarnason, GA; Choueiri, TK; Dezzani, L; Grünwald, V; Han, J; Hutson, TE; Kollmannsberger, C; Motzer, RJ; Porta, C; Sternberg, CN; Tannir, NM	1
de Geeter, P; Decker, T; Quiering, C; Resch, A; Schmitz, S; Schostak, M	1
Desar, IME; Steeghs, N; van der Graaf, WTA; van Erp, NP; Westerdijk, K	1
Akgül Babacan, N; Akın Telli, T; Alan, Ö; Alsan Çetin, İ; Arıkan, R; Başoğlu Tüylü, T; Çiçek, FC; Dane, F; Demircan, NC; Ercelep, Ö; Ergelen, R; Kaya, S; Öztürk, MA; Tinay, İ; Yumuk, PF	1
Azam, C; Bardies, C; Canonge, JM; Chevreau, C; Claraz, P; Cottura, E; Guibaud, S; Le Goff, M; Mourey, L; Pelagatti, V; Pollet, O; Pouessel, D; Puisset, F; Vinson, C	1
Albuquerque, EV; Bastos, DA; Bonadio, RC; Cavalcante, A; Coelho, RF; Cordeiro, MD; Nahas, WC; Pontes, J; Sarkis, AS; Sierra, PS	1
Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M	1
Guo, J; He, Z; Huang, Y; Jin, J; Qin, S; Ren, X; Sheng, X; Wang, B; Wang, J; Ye, D; Zhang, X; Zhou, A; Zhou, F	1
Albersen, M; Baldewijns, M; Beuselinck, B; Bourgain, C; Debruyne, PR; Haaker, L; Laenen, A; Laguerre, B; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Roussel, E; Tryssesoone, L; Van den Bulck, H; Verbiest, A; Wynendaele, W	1
Achkhanian, J; Nowak-Sliwinska, P; Rausch, M; Rotari, A; Weiss, A	1
Bastos, DA; Bonadio, RRC; de Azevedo Souza, MCL; Dzik, C; Faraj, SF; Isaacsson Velho, P; Muniz, DQB; Nader Marta, G; Nardo, M	1
Azzouz, F; Braychenko, E; Elaidi, R; Epaillard, N; Moreira, M; Oudard, S; Simonaggio, A; Sun, CM; Thibault, C; Vano, YA	1
Feng, C; Li, Y; Shen, Y; Wen, H; Zhu, Z	1
Eisen, T; Fife, K; Gordon, J; Hawkins, R; Hurst, M; Matakidou, A; Naicker, N; Nolasco, S; Wang, M	1
Barzaghi, P; Perego, G; Petrelli, F; Vavassori, I	1
Albersen, M; Baldewijns, M; Beuselinck, B; Caruso, S; Couchy, G; García-Donas, J; Graña-Castro, O; Laenen, A; Rodriguez-Antona, C; Roussel, E; Schöffski, P; Van Hoef, V; Verbiest, A; Wozniak, A; Zucman-Rossi, J	1
Basso, U; Bergo, E; Bimbatti, D; Brunello, A; Lamberti, E; Maruzzo, M; Pierantoni, F; Tierno, G; Zagonel, V	1
Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y	1
Capri, S; Condorelli, C; Kalra, M; Khare, A; Modi, N; Porta, C; Premoli, E; Ratto, B	1
Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E	1
Hayashi, T; Ijiri, Y; Imano, H; Kato, R	1
Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G	1
Bondarenko, A; Borisov, P; Tishova, Y; Tsimafeyeu, I; Zakurdaeva, K; Zukov, R	1
Dahlem, R; Fisch, M; Fühner, C; Hillemacher, T; Janisch, F; Kienapfel, C; Klotzbücher, T; Marks, P; Meyer, CP; Mori, K; Mostafei, H; Rink, M; Shariat, SF; Yu, H	1
Kargar, M; Sadeghi, S	1
Brezinová, B; Chovanec, M; Dubovan, P; Gomolčáková, J; Jurišová, S; Mardiak, J; Mego, M; Rejlekova, K	1
Borikun, TV; Pikul, MV; Rossylna, OV; Semko, SL; Stakhovsky, EO; Vitruk, Yu V; Voylenko, OA; Yalovenko, TM; Zadvornyi, TV	1
Bendová, B; Büchler, T; Fiala, O; Filipovský, J; Fínek, J; Hora, M; Ostašov, P; Rozsypalová, A; Šorejs, O; Šustr, J; Trávníček, I	1
Agarwal, N; Appleman, LJ; Bhavsar, NA; Borham, A; Costello, BA; Fishman, MN; Gartrell, BA; George, DJ; Hammers, HJ; Harrison, MR; Hussain, A; Hutson, TE; Jim, H; Kyriakopoulos, CE; Mardekian, J; Molina, AM; Pachynski, RK; Pal, SK; Ryan, CW; Stadler, WM; Tsao, CK; Vaishampayan, U; Zakharia, Y	1
Krens, SD; Mulder, SF; van Erp, NP	1
Amaro, F; Bastos, ML; Carvalho, M; Guedes de Pinho, P; Pinto, J; Pisoeiro, C; Valente, MJ	1
Alfsen, GC; Farkas, L; Geisler, J; Kristensen, VN; Müller, S; Naji, F; Nilsen, FS; Oldenburg, J; Puco, K; Tahiri, A	1
Alam, S; Ghosh-Ray, S; Gogbashian, A; Lakhani, A; Nathan, P; Padhani, A; Sharma, A	1
Carducci, MA	1

Reviews

75 review(s) available for indazoles and su 11248

Article	Year
SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clinical genitourinary cancer, 2005, Volume: 4, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib	2005
[Progress in therapeutic strategy for renal cell carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2006
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2006
Molecular targeting therapy for renal cell carcinoma. International journal of clinical oncology, 2006, Volume: 11, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib	2006
New treatment approaches in metastatic renal cell carcinoma. Current opinion in urology, 2006, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2006
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-15, Volume: 13, Issue:2 Pt 2 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Phenotype; Platelet-Derived Growth Factor; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2007
[Oral drugs inhibiting the VEGF pathway]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2007
Novel drugs for renal cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2008
Targeted therapies in metastatic renal cancer in 2009. BJU international, 2009, Volume: 103, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors	2009
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer, 2009, May-15, Volume: 115, Issue:10 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2009
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome	2009
Tyrosine kinase inhibitors and the thyroid. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:6 Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms	2009
Compounds in clinical Phase III and beyond. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 180 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A	2010
Targeted molecular therapies in thyroid carcinoma. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:9 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms	2009
[Antiangionic drugs in soft tissue sarcoma]. Bulletin du cancer, 2010, Volume: 97, Issue:6 Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2010
[Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines]. Magyar onkologia, 2010, Volume: 54, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Europe; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2010
In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment	2011
[Novelties in the treatment for advanced renal-cell cancer]. Orvosi hetilap, 2011, Apr-24, Volume: 152, Issue:17 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
[Treatment of metastatic renal cell carcinoma]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2011, Volume: 21, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2011
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. Clinical therapeutics, 2011, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib	2011
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. Hematology/oncology clinics of North America, 2011, Volume: 25, Issue:4 Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2011
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?]. Bulletin du cancer, 2011, Volume: 98, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib	2011
[Systemic treatment of renal cell carcinoma - recent update]. Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:15-16 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib	2011
[Dermatologic side effects induced by new angiogenesis inhibitors]. Bulletin du cancer, 2011, Volume: 98, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib	2011
Tyrosine kinase inhibitors for metastatic renal cell carcinoma. Drug and therapeutics bulletin, 2011, Volume: 49, Issue:11 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2011
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing	2012
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8 Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib	2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. Magyar onkologia, 2012, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib	2012
Current treatment considerations in metastatic renal cell carcinoma. Current treatment options in oncology, 2012, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology, 2012, Volume: 83, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. American journal of clinical oncology, 2014, Volume: 37, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2	2014
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anti-cancer drugs, 2013, Volume: 24, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid	2013
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. Annales de dermatologie et de venereologie, 2013, Volume: 140, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles	2013
Side-effects associated with targeted therapies in renal cell carcinoma. Current opinion in supportive and palliative care, 2013, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib	2013
Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Seminars in oncology, 2013, Volume: 40, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib	2013
Molecular markers to predict response to therapy. Seminars in oncology, 2013, Volume: 40, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein	2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer treatment reviews, 2014, Volume: 40, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. International journal of cancer, 2014, Aug-15, Volume: 135, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting	2014
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. International journal of cancer, 2015, Jan-01, Volume: 136, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib	2015
Emerging therapeutic targets for synovial sarcoma. Expert review of anticancer therapy, 2014, Volume: 14, Issue:7 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases	2014
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis, 2014, Volume: 17, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2014
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Critical reviews in oncology/hematology, 2014, Volume: 92, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib	2014
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC cancer, 2014, Aug-15, Volume: 14 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis	2014
Combining targeted agents with modern radiotherapy in soft tissue sarcomas. Journal of the National Cancer Institute, 2014, Volume: 106, Issue:11 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment	2014
Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors. Pancreas, 2014, Volume: 43, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Differentiation; Chemoradiotherapy; Clinical Trials as Topic; Drugs, Investigational; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radioisotopes; Sirolimus; Somatostatin; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2014
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A	2015
Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews. Urology, 2015, Volume: 12, Issue:2 Topics: Angiogenesis Inhibitors; Carcinogenesis; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Nephrons; Organ Sparing Treatments; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2015
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for The oncologist, 2015, Volume: 20, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Europe; Humans; Imidazoles; Indazoles; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2015
First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES. Current opinion in urology, 2015, Volume: 25, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Signal Transduction; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome	2015
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Targeted oncology, 2015, Volume: 10, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A	2015
Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment. International journal of urology : official journal of the Japanese Urological Association, 2016, Volume: 23, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Metastasectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Pyrroles; Sunitinib	2016
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]. Aktuelle Urologie, 2015, Volume: 46, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2015
Clinical management of metastatic kidney cancer: the role of new molecular drugs. Future oncology (London, England), 2016, Volume: 12, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2016
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews. Clinical genitourinary cancer, 2016, Volume: 14, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2016
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. Bulletin du cancer, 2016, Volume: 103, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2016
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anti-cancer drugs, 2016, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism]. Der Urologe. Ausg. A, 2016, Volume: 55, Issue:5 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib	2016
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib	2016
Systemic therapy in metastatic renal cell carcinoma. World journal of urology, 2017, Volume: 35, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2017
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer treatment reviews, 2016, Volume: 50 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European urology, 2017, Volume: 71, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2017
Targeted Therapy for Metastatic Renal Cell Carcinoma. Acta medica Indonesiana, 2016, Volume: 48, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult	2017
Renal cell carcinoma. Nature reviews. Disease primers, 2017, Mar-09, Volume: 3 Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2017
The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. Future oncology (London, England), 2018, Volume: 14, Issue:9 Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indazoles; Indoles; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib	2018
Adjuvant therapy after nephrectomy for renal cell carcinoma. Asia-Pacific journal of clinical oncology, 2018, Volume: 14 Suppl 5 Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Progression-Free Survival; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib	2018
Bulletin du cancer, 2018, Volume: 105 Suppl 3 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib	2018
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC cancer, 2019, May-23, Volume: 19, Issue:1 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Health Care Costs; Humans; Indazoles; Kidney Neoplasms; Liver; Middle Aged; Neutropenia; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome	2019
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. Future oncology (London, England), 2019, Volume: 15, Issue:22 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2019
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose. British journal of clinical pharmacology, 2020, Volume: 86, Issue:2 Topics: Antineoplastic Agents; Drug Monitoring; Humans; Imatinib Mesylate; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib	2020
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer treatment reviews, 2020, Volume: 84 Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib	2020
Targeted therapy for metastatic renal cell carcinoma. The Cochrane database of systematic reviews, 2020, 10-14, Volume: 10 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2020
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Internal and emergency medicine, 2021, Volume: 16, Issue:5 Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2021

Trials

38 trial(s) available for indazoles and su 11248

Article	Year
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. Clinical therapeutics, 2011, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib	2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyrroles; Sunitinib; Treatment Failure	2011
An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2012
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:3 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome	2013
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment	2013
Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial. Clinical genitourinary cancer, 2013, Volume: 11, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome	2013
Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sulfonamides; Sunitinib; Survival Rate; Treatment Failure	2014
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. The New England journal of medicine, 2013, Aug-22, Volume: 369, Issue:8 Topics: Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib	2013
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult	2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-10, Volume: 32, Issue:14 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Double-Blind Method; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Patient Preference; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires	2014
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. The New England journal of medicine, 2014, May-01, Volume: 370, Issue:18 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British journal of cancer, 2014, Jun-10, Volume: 110, Issue:12 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden	2014
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2014
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib]. Der Urologe. Ausg. A, 2015, Volume: 54, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib	2015
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Female; Gene Expression; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Lymphocyte Count; Macrophages; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2015
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Renal Cell; China; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A	2015
Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma. Cancer, 2016, Jan-15, Volume: 122, Issue:2 Topics: Adult; Aged; Carcinoma, Renal Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Indazoles; Indoles; Kidney Neoplasms; Lymph Nodes; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Risk Assessment; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome	2016
Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. International journal of cancer, 2016, May-01, Volume: 138, Issue:9 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? European journal of cancer (Oxford, England : 1990), 2016, Volume: 53 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2016
Benefits of pazopanib over sunitinib for renal cell carcinoma. The Lancet. Oncology, 2016, Volume: 17, Issue:3 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Patient Safety; Prognosis; Pyrimidines; Pyrroles; Quality of Life; Sensitivity and Specificity; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2016
Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer, 2016, Apr-01, Volume: 122, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib; Young Adult	2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome	2016
Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. British journal of cancer, 2016, 06-14, Volume: 114, Issue:12 Topics: Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Proteinuria; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A	2016
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult	2017
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated BMC cancer, 2017, 06-02, Volume: 17, Issue:1 Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome	2017
Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort. World journal of urology, 2018, Volume: 36, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Pyrimidines; Regression Analysis; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib; Treatment Outcome; Tumor Burden	2018
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. Journal of hematology & oncology, 2018, 05-22, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Sunitinib; White People; Young Adult	2018
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British journal of cancer, 2018, Volume: 119, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome	2018
Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. Clinical drug investigation, 2018, Volume: 38, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Canada; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Pyrimidines; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Treatment Outcome	2018
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer, 2018, 10-22, Volume: 6, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyrimidines; Sulfonamides; Sunitinib	2018
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International journal of clinical oncology, 2019, Volume: 24, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2019
Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol. Health and quality of life outcomes, 2019, Feb-04, Volume: 17, Issue:1 Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult	2019
Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions Chemical research in toxicology, 2020, 01-21, Volume: 33, Issue:1 Topics: Aldehydes; Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Indazoles; Microsomes, Liver; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Serum Albumin, Human; Sulfonamides; Sunitinib	2020
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clinical genitourinary cancer, 2019, Volume: 17, Issue:6 Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Kidney Neoplasms; Logistic Models; Male; Pyrimidines; Random Allocation; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2019
A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ). Urologia internationalis, 2020, Volume: 104, Issue:3-4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrimidines; Sulfonamides; Sunitinib; Treatment Failure; Treatment Outcome	2020
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. BMC cancer, 2020, Mar-14, Volume: 20, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; China; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Sulfonamides; Sunitinib; Young Adult	2020
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin du cancer, 2020, Volume: 107, Issue:5S Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Neoplasm Metastasis; Nivolumab; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib	2020
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES. American journal of clinical oncology, 2021, 04-01, Volume: 44, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fatigue; Follow-Up Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Quality of Life; Sulfonamides; Sunitinib; Testosterone	2021

Other Studies

170 other study(ies) available for indazoles and su 11248

Article	Year
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU international, 2006, Volume: 98, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease	2006
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer, 2007, Aug-01, Volume: 110, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A	2007
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease	2008
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. British journal of cancer, 2009, Nov-17, Volume: 101, Issue:10 Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Myelopoiesis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Substrate Specificity; Sulfonamides; Sunitinib	2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood, 2010, Feb-18, Volume: 115, Issue:7 Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib	2010
Prognostic factors in patients treated with VEGF-targeted therapies. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors	2010
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicologic pathology, 2010, Volume: 38, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Echocardiography; Heart; Immunohistochemistry; In Situ Nick-End Labeling; Indazoles; Indoles; Male; Microscopy, Electron, Transmission; Mitochondria; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Rats; Sorafenib; Sulfonamides; Sunitinib; Troponin I	2010
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert opinion on biological therapy, 2010, Volume: 10, Issue:11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2010
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:6 Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured	2011
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urologie, 2011, Volume: 42, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. The Canadian journal of urology, 2011, Volume: 18, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Indazoles; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2011
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. Journal of biochemistry, 2012, Volume: 151, Issue:1 Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection	2012
Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology, 2011, Volume: 78, Issue:4 Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Sulfonamides; Sunitinib	2011
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult	2012
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report. Anticancer research, 2012, Volume: 32, Issue:2 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2012
Second-line treatment for renal cell cancer. British journal of cancer, 2012, Feb-14, Volume: 106, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Retreatment; Sulfonamides; Sunitinib	2012
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis	2012
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States	2013
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position. Clinical genitourinary cancer, 2013, Volume: 11, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2013
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer treatment reviews, 2013, Volume: 39, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2013
Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Female; Gene Expression; Humans; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrimidines; Pyrroles; Sirolimus; Stearoyl-CoA Desaturase; Sulfonamides; Sunitinib; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays	2013
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013, Volume: 71, Issue:9 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid	2013
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4 Topics: Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Necrosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Sulfonamides; Sunitinib; Urinary Bladder Neoplasms	2013
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Sep-15, Volume: 19, Issue:18 Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays	2013
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). International journal of radiation oncology, biology, physics, 2013, Sep-01, Volume: 87, Issue:1 Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Bevacizumab; Duodenal Diseases; Humans; Indazoles; Indoles; Intestinal Diseases; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography; Radiosurgery; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Stomach Ulcer; Sulfonamides; Sunitinib; Ulcer	2013
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib	2013
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:11 Topics: Bilirubin; Biomarkers, Pharmacological; Genetic Association Studies; Genotype; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Indoles; Liver; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib	2013
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. International urology and nephrology, 2014, Volume: 46, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A	2014
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction. CNS neuroscience & therapeutics, 2014, Volume: 20, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Apoptosis; Cells, Cultured; Cerebellum; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; Humans; Indazoles; Indoles; Neurons; Neuroprotective Agents; Neurotoxins; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib	2014
Pazopanib outscores sunitinib on tolerability. Cancer discovery, 2014, Volume: 4, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Sunitinib	2014
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4 Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African	2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. European urology, 2014, Volume: 66, Issue:3 Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid	2014
How to interpret patient preferences in selecting the best drug: are the current measurements up to the job? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-10, Volume: 32, Issue:14 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Patient Preference; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2014
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy. Journal of surgical oncology, 2014, Volume: 110, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis	2014
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2014, Volume: 17, Issue:4 Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib	2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clinical genitourinary cancer, 2014, Volume: 12, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. Clinical genitourinary cancer, 2014, Volume: 12, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2014
In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2014
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma. BMC cancer, 2014, Jun-06, Volume: 14 Topics: Aged; Carcinoma, Renal Cell; Cone-Beam Computed Tomography; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome	2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. The Journal of urology, 2015, Volume: 193, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2015
Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:4 Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2015
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2015
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. Journal of medical economics, 2015, Volume: 18, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Health Expenditures; Health Services; Humans; Imidazoles; Indazoles; Indoles; Markov Chains; Models, Econometric; Pyrroles; Quality-Adjusted Life Years; Sunitinib; United States	2015
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. European urology, 2015, Volume: 68, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Withholding Treatment	2015
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy? Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2015
Health care costs among renal cancer patients using pazopanib and sunitinib. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:1 Topics: Carcinoma, Renal Cell; Female; Health Care Costs; Health Services; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; United States	2015
Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:1 Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Pyrimidines; Pyrroles; Quality of Life; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis; United States	2015
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cellular oncology (Dordrecht), 2015, Volume: 38, Issue:2 Topics: Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Tandem Mass Spectrometry	2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British journal of cancer, 2015, Mar-31, Volume: 112, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Interleukin-8; Kidney Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides; Sunitinib; Survival Analysis; Young Adult	2015
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Scientific reports, 2015, Mar-11, Volume: 5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden	2015
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7 Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib	2015
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats. Reproductive sciences (Thousand Oaks, Calif.), 2015, Volume: 22, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2015
Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis. Journal of managed care & specialty pharmacy, 2015, Volume: 21, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medication Adherence; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States	2015
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. American journal of hypertension, 2016, Volume: 29, Issue:2 Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness	2016
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU international, 2016, Volume: 117, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome	2016
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications. The Canadian journal of urology, 2015, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate	2015
[Systemic therapy of soft tissue sarcomas]. Voprosy onkologii, 2015, Volume: 61, Issue:2 Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2015
Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer immunology, immunotherapy : CII, 2015, Volume: 64, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Everolimus; Female; Humans; Immunotherapy; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; T-Lymphocytes; Treatment Outcome	2015
Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma. Chinese medical journal, 2015, Aug-05, Volume: 128, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein; Young Adult	2015
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs. Oncotarget, 2015, Sep-29, Volume: 6, Issue:29 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome	2015
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. Journal of oncology practice, 2015, Volume: 11, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Current medical research and opinion, 2015, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cohort Studies; Drug Costs; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Medicare; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United States; Young Adult	2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2016
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom	2016
Murine colitis treated with multitargeted tyrosine kinase inhibitors. The Journal of surgical research, 2016, Volume: 200, Issue:2 Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome	2016
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin Cancer, 2016, Feb-01, Volume: 122, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:9 Topics: Animals; Antineoplastic Agents; Axitinib; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2016
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Journal of medical economics, 2016, Volume: 19, Issue:5 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2016
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment	2016
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. Oncology reports, 2016, Volume: 35, Issue:3 Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Neoplastic Stem Cells; Niacinamide; Oxygen; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Microenvironment	2016
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Current medical research and opinion, 2016, Volume: 32, Issue:4 Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States	2016
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. European urology, 2016, Volume: 70, Issue:3 Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment	2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC). Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover--The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology, 2016, Volume: 90, Issue:3 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Cross-Over Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis	2016
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult	2016
[NEOADJUVANT TARGET THERAPY IN A RENAL-CELL CANCER]. Klinichna khirurhiia, 2015, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2015
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC cancer, 2016, Mar-29, Volume: 16 Topics: Adult; Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2016
[Systemic therapy of metastatic renal cell carcinoma]. Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:7 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2016
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget, 2016, Jun-21, Volume: 7, Issue:25 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genotype; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Aged; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States	2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. European urology, 2016, Volume: 70, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden	2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget, 2016, Jul-05, Volume: 7, Issue:27 Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays	2016
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry. BMC cancer, 2016, 06-11, Volume: 16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Prescriptions; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Molecular Targeted Therapy; Netherlands; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult	2016
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer medicine, 2016, Volume: 5, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; CD28 Antigens; Chemotherapy, Adjuvant; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Nephrectomy; Preoperative Period; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A; Young Adult	2016
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Carcinoma, Renal Cell; Exome Sequencing; Female; Fumarate Hydratase; GRB2 Adaptor Protein; Humans; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult	2017
Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Young Adult	2016
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3 Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Female; Health Care Costs; Humans; Indazoles; Indoles; Male; Middle Aged; Prescription Fees; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult	2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors	2016
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. BMC cancer, 2016, 08-02, Volume: 16 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2016
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European journal of cancer (Oxford, England : 1990), 2016, Volume: 65 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib	2016
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget, 2016, Jun-21, Volume: 7, Issue:25 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays	2016
Changes in metabolic profile, iron and ferritin levels during the treatment of metastatic renal cancer - A new potential biomarker? Medical hypotheses, 2016, Volume: 94 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cholesterol; Ferritins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypothyroidism; Indazoles; Indoles; Iron; Kidney Neoplasms; Lipids; Metabolome; Models, Theoretical; Neoplasm Metastasis; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Triglycerides	2016
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. International journal of clinical oncology, 2017, Volume: 22, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors	2017
[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases]. Archivos espanoles de urologia, 2016, Volume: 69, Issue:7 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Sunitinib	2016
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden	2017
[Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2016, Sep-23, Volume: 38, Issue:9 Topics: Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Nephrectomy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Anti-cancer drugs, 2017, Volume: 28, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Survival Rate	2017
Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. Cell reports, 2016, 10-25, Volume: 17, Issue:5 Topics: Apoptosis; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Indazoles; Indoles; Oncogenes; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Rhabdoid Tumor; Sulfonamides; Sunitinib	2016
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity. BMC medicine, 2016, Dec-07, Volume: 14, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Genetic Heterogeneity; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pharmacogenomic Testing; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sulfonamides; Sunitinib	2016
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report. The American journal of case reports, 2017, Jan-03, Volume: 18 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome	2017
Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Renal Cell; Female; Humans; Hypertension; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult	2017
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. Clinical genitourinary cancer, 2017, Volume: 15, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2017
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. Clinical therapeutics, 2017, Volume: 39, Issue:3 Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Humans; Indazoles; Indoles; Italy; Kidney Neoplasms; National Health Programs; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Analysis	2017
Re: First-Line Sunitinib versus Pazopanib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. The Journal of urology, 2017, Volume: 197, Issue:3 Pt 1 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Sulfonamides; Sunitinib	2017
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:4 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2017
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Clinical nuclear medicine, 2017, Volume: 42, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib	2017
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. Urologic oncology, 2017, Volume: 35, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult	2017
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. British journal of clinical pharmacology, 2017, Volume: 83, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult	2017
Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells. Cancer science, 2017, Volume: 108, Issue:8 Topics: Autocrine Communication; Axitinib; Breast Neoplasms; Cathepsin G; Cell Aggregation; Female; Humans; Imidazoles; Indazoles; Indoles; Insulin-Like Growth Factor I; MCF-7 Cells; Phosphorylation; Pyrazines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Small Molecule Libraries; Sunitinib	2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic oncology, 2017, Volume: 35, Issue:9 Topics: Aged; Antineoplastic Agents; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome	2017
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PloS one, 2017, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Prognosis; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Sulfonamides; Sunitinib; Survival Rate; United Kingdom	2017
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome	2017
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2017
Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:9 Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Rural Population; Sulfonamides; Sunitinib	2017
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Current medical research and opinion, 2017, Volume: 33, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2017
Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma. Oncology research and treatment, 2017, Volume: 40, Issue:11 Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Cell-Free Nucleic Acids; Combined Modality Therapy; Disease-Free Survival; Everolimus; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2017
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Advances in therapy, 2017, Volume: 34, Issue:11 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Databases, Factual; Female; Health Expenditures; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; United States	2017
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. World journal of urology, 2018, Volume: 36, Issue:3 Topics: Aged; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Nivolumab; Probability; Prognosis; Proportional Hazards Models; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sex Factors; Sulfonamides; Sunitinib; Survival Rate; Thrombocytosis	2018
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. Anticancer research, 2018, Volume: 38, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2018
Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib. Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:3 Topics: Aged; Ammonia; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Stromal Tumors; Humans; Hyperammonemia; Indazoles; Middle Aged; Neurotoxicity Syndromes; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome; Withholding Treatment	2019
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. Acta clinica Belgica, 2019, Volume: 74, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Sectional Studies; Humans; Hypogonadism; Indazoles; Kidney Neoplasms; Luteinizing Hormone; Male; Middle Aged; Molecular Targeted Therapy; Prevalence; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib; Testosterone; Vascular Endothelial Growth Factor A	2019
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Health Care Costs; Health Resources; Humans; Indazoles; Indoles; Insurance Claim Review; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Medicare; Patient Acceptance of Health Care; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Time Factors; Treatment Outcome; United States	2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU international, 2019, Volume: 123, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retreatment; Sulfonamides; Sunitinib; Survival Rate	2019
Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology, 2018, Volume: 73, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Female; Humans; Indazoles; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Pyrimidines; Sulfonamides; Sunitinib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Young Adult	2018
Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites. Journal of medicinal chemistry, 2018, 09-13, Volume: 61, Issue:17 Topics: Aldehydes; Amines; Catalysis; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Humans; Indazoles; Metalloporphyrins; Microsomes, Liver; Oxidation-Reduction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides; Sunitinib	2018
Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population. Journal of global oncology, 2018, Volume: 4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brazil; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; Young Adult	2018
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Carcinoma, Renal Cell; Denosumab; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypocalcemia; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib	2019
Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. Journal of Korean medical science, 2018, Dec-17, Volume: 33, Issue:51 Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2018
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report. BMC nephrology, 2019, 01-03, Volume: 20, Issue:1 Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diabetic Nephropathies; Dihydropyridines; Drug Substitution; Edema; Everolimus; Humans; Hypertension; Indazoles; Kidney Failure, Chronic; Lung Neoplasms; Male; Nephrotic Syndrome; Nivolumab; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2019
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European journal of cancer (Oxford, England : 1990), 2019, Volume: 108 Topics: Adult; Aged; Anilides; Antineoplastic Agents, Immunological; Axitinib; Carcinoma, Renal Cell; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Treatment Failure	2019
Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2019
Checkpoint Inhibitor-TKI Combos Effective in RCC. Cancer discovery, 2019, Volume: 9, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Sunitinib	2019
Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging. Scientific reports, 2019, 03-20, Volume: 9, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Carcinoma, Renal Cell; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Contrast Media; Humans; Image Interpretation, Computer-Assisted; Indazoles; Kidney Neoplasms; Microvessels; Models, Biological; Neovascularization, Pathologic; Phantoms, Imaging; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Ultrasonography	2019
Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. Targeted oncology, 2019, Volume: 14, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Molecular Targeted Therapy; Neutrophils; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate	2019
Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors. The oncologist, 2019, Volume: 24, Issue:7 Topics: Aged; Carcinoma, Renal Cell; Female; Heart Failure; Humans; Indazoles; Kidney Neoplasms; Leiomyosarcoma; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib	2019
Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution. Clinical genitourinary cancer, 2019, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom	2019
Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Folic Acid; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome	2019
Real-World Evidence Data on Metastatic Renal-Cell Carcinoma Treatment in Austria: The RELACS Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:5 Topics: Aged; Antineoplastic Agents; Austria; Carcinoma, Renal Cell; Clinical Decision-Making; Electronic Health Records; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sex Characteristics; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome	2019
Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. International journal of radiation oncology, biology, physics, 2019, 10-01, Volume: 105, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Confidence Intervals; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pyrimidines; Quality of Life; Radiosurgery; Regression Analysis; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Tomography, X-Ray Computed	2019
[Cost-effectiveness between pazopanib and sunitinib for metastatic renal cancer from the perspective of the Brazilian Unified National Health System]. Cadernos de saude publica, 2019, Aug-22, Volume: 35, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Female; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; National Health Programs; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome	2019
Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer medicine, 2019, Volume: 8, Issue:15 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; United States; United States Department of Veterans Affairs	2019
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:5 Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib	2020
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. European journal of clinical pharmacology, 2020, Volume: 76, Issue:4 Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Indazoles; Male; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib	2020
Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era. Clinical genitourinary cancer, 2020, Volume: 18, Issue:2 Topics: Adolescent; Adult; Age Factors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Sulfonamides; Sunitinib; Young Adult	2020
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. Urologic oncology, 2020, Volume: 38, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome	2020
Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. British journal of cancer, 2020, Volume: 123, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Indazoles; Kidney Neoplasms; Models, Theoretical; Piperazines; Pyrazoles; Signal Transduction; Small Molecule Libraries; Sulfonamides; Sunitinib	2020
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma. Pathology oncology research : POR, 2020, Volume: 26, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Child; Female; Humans; Indazoles; Inflammation; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Platelet Count; Prognosis; Pyrimidines; Sulfonamides; Sunitinib; Young Adult	2020
Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation. Cancer medicine, 2020, Volume: 9, Issue:16 Topics: Anilides; Antineoplastic Agents; Arylsulfotransferase; Axitinib; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Chromogranins; Computer Simulation; Cyclin E; DNA Copy Number Variations; Drug Resistance, Neoplasm; GTP-Binding Protein alpha Subunits, Gs; Humans; Indazoles; Kidney Neoplasms; Oncogene Proteins; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2020
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC cancer, 2020, Jul-17, Volume: 20, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom; Young Adult	2020
Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. Medical oncology (Northwood, London, England), 2020, Aug-07, Volume: 37, Issue:9 Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Patient Selection; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib	2020
MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PloS one, 2020, Volume: 15, Issue:9 Topics: Carcinoma, Renal Cell; Female; Gene Expression Profiling; Humans; Indazoles; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Pyrimidines; RNA, Messenger; Sulfonamides; Sunitinib; Survival Analysis	2020
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience. Journal of geriatric oncology, 2021, Volume: 12, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Geriatric Assessment; Humans; Indazoles; Kidney Neoplasms; Male; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2021
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. Journal of medical economics, 2020, Volume: 23, Issue:12 Topics: Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indazoles; Italy; Kidney Neoplasms; Pyrimidines; Quality-Adjusted Life Years; State Medicine; Sulfonamides; Sunitinib	2020
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan. JAMA network open, 2020, 11-02, Volume: 3, Issue:11 Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States	2020
Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 71 Topics: Antineoplastic Agents; Axitinib; Caspases; HMGB1 Protein; Humans; Indazoles; Indoles; Inflammasomes; Interleukin-1beta; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; THP-1 Cells	2021
Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World journal of urology, 2021, Volume: 39, Issue:8 Topics: Alanine Transaminase; Aspartate Aminotransferases; Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Female; Humans; Indazoles; Karnofsky Performance Status; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2021
Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors? European journal of clinical pharmacology, 2021, Volume: 77, Issue:9 Topics: Cytochrome P-450 CYP3A; Humans; Indazoles; Pyrimidines; Sulfonamides; Sunitinib	2021
Targeted therapy in Xp11 translocation renal cell carcinoma. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2021,Spring, Volume: 34, Issue:2 Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Chromosomes, Human, X; Crizotinib; Disease Progression; Everolimus; Fatal Outcome; Female; Humans; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Nivolumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Sorafenib; Sulfonamides; Sunitinib; Tomography, X-Ray Computed	2021
Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue. Experimental oncology, 2021, Volume: 43, Issue:2 Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2021
Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line. Targeted oncology, 2021, Volume: 16, Issue:5 Topics: Aged; Carcinoma, Renal Cell; Cardiovascular Agents; Disease-Free Survival; Humans; Indazoles; Indoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome	2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clinical genitourinary cancer, 2022, Volume: 20, Issue:1 Topics: Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Male; Prospective Studies; Quality of Life; Registries; Retrospective Studies; Sunitinib; Treatment Outcome	2022
Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:2 Topics: Aged; Ascites; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Humans; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Treatment Outcome	2022
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety. International journal of molecular sciences, 2022, Aug-31, Volume: 23, Issue:17 Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Renal Cell; Glycerophospholipids; Humans; Indazoles; Kidney Neoplasms; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2022
Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors. Oncotarget, 2022, Volume: 13 Topics: Anilides; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Nerve Growth Factors; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; src-Family Kinases; Sulfonamides; Sunitinib	2022
Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib. Anticancer research, 2023, Volume: 43, Issue:2 Topics: Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Lipomatosis; Protein Kinase Inhibitors; Sunitinib	2023
Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 04-10, Volume: 41, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Interferon-alpha; Kidney Neoplasms; Pyrroles; Sunitinib	2023